Results for the US Phase IIb clinical study have been delayed by a quarter to mid-2020, so investors’ attention will now turn to the YE19 study update. However, Destiny’s H119 results showed continuing prudent management and targeted resourcing of the clinical programme, with grant income and a regulatory backdrop that supports novel antimicrobial development.
24 Sep 2019
Destiny Pharma - Careful resourcing, supportive environment
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Destiny Pharma - Careful resourcing, supportive environment
Destiny Pharma Plc (DEST:LON) | 26.0 -0.4 (-5.5%) | Mkt Cap: 24.8m
- Published:
24 Sep 2019 -
Author:
Dr Andy Smith -
Pages:
3
Results for the US Phase IIb clinical study have been delayed by a quarter to mid-2020, so investors’ attention will now turn to the YE19 study update. However, Destiny’s H119 results showed continuing prudent management and targeted resourcing of the clinical programme, with grant income and a regulatory backdrop that supports novel antimicrobial development.